Patents Assigned to INSTITUTE OF MOLECULAR GENETICS AS CR, V.V.I.
  • Patent number: 11771712
    Abstract: Disclosed herein are compounds comprising dicarba-closo-dodecaborane. The compounds can be, for example, estrogen receptor beta (ER?) agonists. In some examples, the compounds can be selective ER? agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof, by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: October 3, 2023
    Assignees: OHIO STATE INNOVATION FOUNDATION, INSTITUTE OF MOLECULAR GENETICS AS CR, V.V.I.
    Inventors: Werner Tjarks, Petr Bartunek, David Sedlak
  • Patent number: 11020411
    Abstract: Disclosed herein are compounds comprising dicarba-closo-dodecaborane. The compounds can be, for example, estrogen receptor beta (ER?) agonists. In some examples, the compounds can be selective ER? agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: June 1, 2021
    Assignees: OHIO STATE INNOVATION FOUNDATION, INSTITUTE OF MOLECULAR GENETICS AS CR, V.V.I.
    Inventors: Werner Tjarks, Petr Bartunek, David Sedlak
  • Publication number: 20180264017
    Abstract: Disclosed herein are compounds comprising dicarba-closo-dodecaborane. The compounds can be, for example, estrogen receptor beta (ER?) agonists. In some examples, the compounds can be selective ER? agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 19, 2016
    Publication date: September 20, 2018
    Applicants: OHIO STATE INNOVATION FOUNDATION, INSTITUTE OF MOLECULAR GENETICS AS CR, V.V.I.
    Inventors: Werner TJARKS, Petr BARTUNEK, David SEDLAK